Dengue Vaccine QDENGA Approved in India
Drug Controller General of India granted market authorisation to Takeda Biopharmaceuticals India’s QDENGA (TAK‑003), India’s first approved dengue vaccine. It is a live-attenuated tetravalent vaccine covering all four dengue serotypes, given as two 0.5 ml subcutaneous doses three months apart for ages 4–60 years, without pre-vaccination screening. WHO recommends it for high-transmission endemic areas; WHO prequalification enables UNICEF/PAHO procurement. Licensed in 43 countries.
The Hindu


